A Double-Blind, Cross-Over, Study of Oral N-Acetylcysteine in Sjögren’s Syndrome
This 1986 double-blind, cross-over trial evaluated the efficacy of oral N-acetylcysteine (NAC) in 26 patients with primary or secondary Sjögren’s syndrome over a four-week period. Baseline assessments revealed significantly elevated salivary lactoferrin levels and decreased tear lysozyme levels compared to healthy controls. Following NAC treatment (200 mg three times daily),